COPD

The FDA has approved revefenacin (YUPELRI) for the maintenance treatment of chronic obstructive pulmonary disease.

Until recently, studies of systemic corticosteroids in pneumonia have yielded contradicting results, while studies in acute exacerbation of COPD have shown significant benefits.

The most reliable practice for helping a patient quit is comprehensive, and catered to their medical, physical, and financial goals.

Patients with inappropriate medication use lived farther from their preferred pharmacy than those with appropriate use—a median distance difference of just more than 1 mile.

The interleukin pathway-targeting monoclonal antibody has been previously approved for adult atopic dermatitis, and is being considered for a handful more inflammatory or allergic conditions.

Results connecting breathlessness catastrophizing with reduced quality of life also have implications for populations with asthma or COPD.